S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
EV Battery Maker Freyr Set For Major Global Expansion
Can A.I. Launch You into Your Next Trading Frontier? (Ad)pixel
Want to Increase Your Conversion Rates? This Is the Biggest Threat to Your Success.
Russia accused of 'kidnapping' head of Ukraine nuclear plant
Can A.I. Launch You into Your Next Trading Frontier? (Ad)pixel
MarketBeat: Week in Review 9/26 – 9/30
EU chief: New Greece-Bulgaria gas pipeline 'means freedom'
Can A.I. Launch You into Your Next Trading Frontier? (Ad)pixel
West rejects Putin's claim it sabotaged Baltic gas pipelines
Danish Energy Agency says Nord Stream 2 gas pipeline under Baltic Sea appears to have stopped leaking gas
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
EV Battery Maker Freyr Set For Major Global Expansion
Can A.I. Launch You into Your Next Trading Frontier? (Ad)pixel
Want to Increase Your Conversion Rates? This Is the Biggest Threat to Your Success.
Russia accused of 'kidnapping' head of Ukraine nuclear plant
Can A.I. Launch You into Your Next Trading Frontier? (Ad)pixel
MarketBeat: Week in Review 9/26 – 9/30
EU chief: New Greece-Bulgaria gas pipeline 'means freedom'
Can A.I. Launch You into Your Next Trading Frontier? (Ad)pixel
West rejects Putin's claim it sabotaged Baltic gas pipelines
Danish Energy Agency says Nord Stream 2 gas pipeline under Baltic Sea appears to have stopped leaking gas
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
EV Battery Maker Freyr Set For Major Global Expansion
Can A.I. Launch You into Your Next Trading Frontier? (Ad)pixel
Want to Increase Your Conversion Rates? This Is the Biggest Threat to Your Success.
Russia accused of 'kidnapping' head of Ukraine nuclear plant
Can A.I. Launch You into Your Next Trading Frontier? (Ad)pixel
MarketBeat: Week in Review 9/26 – 9/30
EU chief: New Greece-Bulgaria gas pipeline 'means freedom'
Can A.I. Launch You into Your Next Trading Frontier? (Ad)pixel
West rejects Putin's claim it sabotaged Baltic gas pipelines
Danish Energy Agency says Nord Stream 2 gas pipeline under Baltic Sea appears to have stopped leaking gas
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
EV Battery Maker Freyr Set For Major Global Expansion
Can A.I. Launch You into Your Next Trading Frontier? (Ad)pixel
Want to Increase Your Conversion Rates? This Is the Biggest Threat to Your Success.
Russia accused of 'kidnapping' head of Ukraine nuclear plant
Can A.I. Launch You into Your Next Trading Frontier? (Ad)pixel
MarketBeat: Week in Review 9/26 – 9/30
EU chief: New Greece-Bulgaria gas pipeline 'means freedom'
Can A.I. Launch You into Your Next Trading Frontier? (Ad)pixel
West rejects Putin's claim it sabotaged Baltic gas pipelines
Danish Energy Agency says Nord Stream 2 gas pipeline under Baltic Sea appears to have stopped leaking gas
NASDAQ:SWTX

SpringWorks Therapeutics - SWTX Stock Forecast, Price & News

$28.53
+1.38 (+5.08%)
(As of 09/30/2022 12:00 AM ET)
Add
Compare
Today's Range
$26.80
$29.94
50-Day Range
$24.10
$39.66
52-Week Range
$13.60
$77.70
Volume
984,373 shs
Average Volume
1.03 million shs
Market Capitalization
$1.78 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$77.33

SpringWorks Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
171.1% Upside
$77.33 Price Target
Short Interest
Healthy
24.54% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.15mentions of SpringWorks Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$4.92 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($5.36) to ($4.71) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.17 out of 5 stars

Medical Sector

520th out of 1,093 stocks

Biological Products, Except Diagnostic Industry

84th out of 171 stocks

SWTX stock logo

About SpringWorks Therapeutics (NASDAQ:SWTX) Stock

SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors. The company is also developing mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas, as well as Phase 1/2a clinical trial for the treatment of NF1-PN; mirdametinib + lifirafenib, a combination therapy that is in Phase 1b/2 clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat solid tumors. In addition, it develops BGB-3245, an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations, which is in Phase I clinical trial. The company has collaborations with BeiGene, Ltd., GlaxoSmithKline LLC, and Allogene to develop combination approaches with nirogacestat and mirdametinib; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain; and Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor. In addition, the company has clinical collaboration agreement with Janssen Biotech, Inc., Precision BioSciences, Inc., Seagen Inc., and AbbVie, Inc. SpringWorks Therapeutics, Inc. was founded in 2017 and is headquartered in Stamford, Connecticut.

Receive SWTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for SpringWorks Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SWTX Stock News Headlines

SpringWorks Announces Expansion of Global, Non-...
SpringWorks Therapeutics Announces $225 Million...
Sizing Up SpringWorks Therapeutics
SpringWorks Therapeutics Slide Continues
See More Headlines
Receive SWTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for SpringWorks Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SWTX Company Calendar

Last Earnings
8/04/2022
Today
10/01/2022
Next Earnings (Estimated)
11/03/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SWTX
Fax
N/A
Employees
176
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$77.33
High Stock Price Forecast
$103.00
Low Stock Price Forecast
$53.00
Forecasted Upside/Downside
+171.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-173,910,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$35 million
Book Value
$8.58 per share

Miscellaneous

Free Float
44,336,000
Market Cap
$1.78 billion
Optionable
Not Optionable
Beta
0.85

Key Executives

  • Mr. Saqib Islam J.D.Mr. Saqib Islam J.D. (Age 52)
    CEO & Director
    Comp: $1.13M
  • Mr. Francis I. Perier Jr. (Age 62)
    M.B.A., Chief Financial Officer
    Comp: $674.85k
  • Dr. Badreddin Edris Ph.D. (Age 35)
    Chief Operating Officer
    Comp: $844.74k
  • Mr. Bhavesh Ashar (Age 56)
    Chief Commercial Officer
    Comp: $821.61k
  • Dr. Michael F. Burgess M.D. (Age 59)
    MBChB, Ph.D., Head of R&D
    Comp: $810.02k
  • Mr. Michael P. Nofi (Age 51)
    Chief Accounting Officer
  • Ms. Kim Diamond
    VP of Communications & Investor Relations
  • Mr. Herschel S. Weinstein J.D. (Age 66)
    Gen. Counsel & Sec.
  • Mr. Daniel J. Pichl (Age 39)
    Chief People Officer
  • Dr. L. Mary Smith PH.D. (Age 55)
    Chief Devel. Officer













SWTX Stock - Frequently Asked Questions

Should I buy or sell SpringWorks Therapeutics stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for SpringWorks Therapeutics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SWTX shares.
View SWTX analyst ratings
or view top-rated stocks.

What is SpringWorks Therapeutics' stock price forecast for 2022?

3 Wall Street analysts have issued twelve-month price targets for SpringWorks Therapeutics' shares. Their SWTX share price forecasts range from $53.00 to $103.00. On average, they expect the company's stock price to reach $77.33 in the next twelve months. This suggests a possible upside of 171.1% from the stock's current price.
View analysts price targets for SWTX
or view top-rated stocks among Wall Street analysts.

How have SWTX shares performed in 2022?

SpringWorks Therapeutics' stock was trading at $61.98 at the start of the year. Since then, SWTX stock has decreased by 54.0% and is now trading at $28.53.
View the best growth stocks for 2022 here
.

When is SpringWorks Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our SWTX earnings forecast
.

How were SpringWorks Therapeutics' earnings last quarter?

SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) announced its earnings results on Thursday, August, 4th. The company reported ($1.41) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.26) by $0.15. SpringWorks Therapeutics's quarterly revenue was up .0% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.97) earnings per share.

What other stocks do shareholders of SpringWorks Therapeutics own?
When did SpringWorks Therapeutics IPO?

(SWTX) raised $126 million in an initial public offering (IPO) on Friday, September 13th 2019. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. ​J.P. Morgan, Goldman Sachs and Cowen​ ​ served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

What is SpringWorks Therapeutics' stock symbol?

SpringWorks Therapeutics trades on the NASDAQ under the ticker symbol "SWTX."

How do I buy shares of SpringWorks Therapeutics?

Shares of SWTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is SpringWorks Therapeutics' stock price today?

One share of SWTX stock can currently be purchased for approximately $28.53.

How much money does SpringWorks Therapeutics make?

SpringWorks Therapeutics (NASDAQ:SWTX) has a market capitalization of $1.78 billion and generates $35 million in revenue each year. The company earns $-173,910,000.00 in net income (profit) each year or ($4.66) on an earnings per share basis.

How many employees does SpringWorks Therapeutics have?

The company employs 176 workers across the globe.

How can I contact SpringWorks Therapeutics?

SpringWorks Therapeutics' mailing address is 100 WASHINGTON BOULEVARD, STAMFORD CT, 06902. The official website for the company is www.springworkstx.com. The company can be reached via phone at 203-883-9490 or via email at investors@springworkstx.com.

This page (NASDAQ:SWTX) was last updated on 10/1/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.